SCM
ABBV icon

Seascape Capital Management’s AbbVie ABBV Stock Holding History

Seascape Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.14M Buy
28,255
+311
+1% +$69K 1.77% 20
2025
Q4 		$6.38M Buy
27,944
+428
+2% +$97.5K 1.82% 18
2025
Q3 		$6.37M Buy
27,516
+592
+2% +$121K 1.83% 15
2025
Q2 		$5M Sell
26,924
-149
-0.6% -$27.7K 1.58% 21
2025
Q1 		$5.67M Sell
27,073
-471
-2% -$91.6K 1.98% 9
2024
Q4 		$4.89M Buy
27,544
+433
+2% +$79.6K 1.7% 18
2024
Q3 		$5.35M Sell
27,111
-665
-2% -$124K 1.91% 12
2024
Q2 		$4.76M Buy
27,776
+356
+1% +$59K 1.78% 15
2024
Q1 		$4.99M Sell
27,420
-628
-2% -$108K 1.86% 12
2023
Q4 		$4.35M Buy
28,048
+628
+2% +$91.6K 1.83% 11
2023
Q3 		$4.09M Buy
27,420
+154
+0.6% +$22.6K 1.94% 10
2023
Q2 		$3.67M Sell
27,266
-203
-0.7% -$29.8K 1.74% 11
2023
Q1 		$4.38M Sell
27,469
-2,392
-8% -$366K 2.23% 8
2022
Q4 		$4.83M Sell
29,861
-572
-2% -$87.7K 2.63% 5
2022
Q3 		$4.08M Buy
30,433
+1,786
+6% +$256K 2.8% 5
2022
Q2 		$4.39M Buy
28,647
+79
+0.3% +$12.1K 2.66% 6
2022
Q1 		$4.63M Sell
28,568
-305
-1% -$44.3K 2.4% 7
2021
Q4 		$3.91M Buy
28,873
+679
+2% +$80.2K 1.83% 14
2021
Q3 		$3.04M Buy
28,194
+2,210
+9% +$253K 1.56% 23
2021
Q2 		$2.93M Buy
25,984
+404
+2% +$45.5K 1.52% 18
2021
Q1 		$2.77M Buy
25,580
+22
+0.1% +$2.35K 1.54% 17
2020
Q4 		$2.74M Buy
25,558
+1,223
+5% +$118K 1.6% 14
2020
Q3 		$2.13M Sell
24,335
-87
-0.4% -$8.19K 1.35% 21
2020
Q2 		$2.4M Sell
24,422
-1,650
-6% -$145K 1.72% 11
2020
Q1 		$1.99M Buy
26,072
+319
+1% +$27.2K 1.8% 12
2019
Q4 		$2.28M Buy
+25,753
New +$2.14M 1.63% 22

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Seascape Capital Management's ABBV Position: Q1 2026 in Review

Seascape Capital Management increased its AbbVie (ABBV) stake by 1.1% in Q1 2026, buying an estimated $69K and bringing the position to 28,255 shares worth $6.14M. The position accounts for 1.77% of the portfolio, ranked #20.

Seascape Capital Management first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $6.38M in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Seascape Capital Management held 28,255 shares of AbbVie worth $6.14M as of Q1 2026.
  • Seascape Capital Management bought 311 AbbVie shares in Q1 2026, an estimated $69K.
  • AbbVie made up 1.77% of Seascape Capital Management's portfolio in Q1 2026, its #20 holding.
  • Seascape Capital Management first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • Seascape Capital Management's AbbVie position peaked at $6.38M in Q4 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Seascape Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.